DOCSLIB.ORG

WELLCOME TRUST 98-6038021 Number and Street (Or P O Box Number If Mail Is Not Delivered to Street Address ) Room /Suite B Telephone Number ( See Instructions)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WELLCOME TRUST 98-6038021 Number and Street (Or P O Box Number If Mail Is Not Delivered to Street Address ) Room /Suite B Telephone Number ( See Instructions) S teturn of Private Foundation OMB No 1545-0052 Form 990 -PF or Section 4947( a)(1) Trust Treated as Private Foundation Do not enter social security numbers on this form as it may be made public. 20015 Department of the Treasury ► Internal Revenue Service ► Information about Form 990 -PF and its separate instructions is at www.irs.gov/forn For calendar vear 2015 or tax vear beainnina 10/01. 2015 . and ending 0 9 /30. 2016 Name of foundation A Employer identification number THE WELLCOME TRUST 98-6038021 Number and street (or P O box number if mail is not delivered to street address ) Room /suite B Telephone number ( see instructions) GY 215 EUSTON ROAD (011) 44-2076118888 4-- O City or town, state or province, country, and ZIP or foreign postal code N q C If exemption application is ► pending , check here. LONDON, ENGLAND UNITED KINGDOM NW1 2BE G Check all that apply Initial return Initial return of a former public charity D 1 Foreign organizations check here. ► 0 Final return Amended return 2 Foreign organizations meeting the tes t, check. here. and attach ► X Address chan9gea Name chang e comput ation H Check type of organization X Section 501(c)(3) exempt private foundation ILLI E If private foundation status was terminated Section 4947(a)(1) nonexem charitable trust Other taxable foundation pt p rivate under section 507(b)(1)(A), check here . ► I Fair market value of all assets at J Accounting method Cash X Accrual F If the foundation is in a60- month termination end of year (from Part fl, col (e), line D Other (specify) under section 507(b)(1)(B), check here , ► 31, 103, 701, 750 . 16) ► $ (Part 1, column (d) must be on cash basis ) (d) Disbursements Analysis of Revenue and Expenses (The (a) Revenue and total of amounts columns (b) Net investment (c) Adjusted net for charitable In (b), (c), and (d) expb per may not necessarily equal the amounts in Income income purposes oks column (a) (see instructions)) books (cash basis only) 1 Contributions, gifts grants , etc , received ( attach schedule) , 1, 132,013 . the foundation is 2 Check if not required to ► attach Sch B . 3 Interest on savings and temporary cash investments. 4 Dividends and interest from securities . 43-7,523,153. 119, 986, 205. ATCH 1 5a Gross rents . 52, 638, 620. b Net rental income or (loss) 6a Net gain or ( loss) from sale of assets not on line 10 1, 157 , 62 5 , 13 5 . C b Gross sales price for all w assets on line 6a y 7 Capital gain net income (from Part IV, line 2) . 0. IX 8 Net short-term capital gain. 9 Income modifications . 10a Gross sales less returns and allowances . b Less Cost of goods sold c Gross profit or (loss) (attach schedule) . , , , 11 Other income (attach schedule) 4,rZC.H. 2 . , 196, 404, 314. 4,478, 667. 12 Total. Add lines 1 through 11 1, 845, 323, 235. 124, 464, 872. 13 Compensation of officers, directors, trustees , etc 1, 953, 479. 4) 14 Other employee salaries and wages . 72,051,893. 15 Pension plans, employee benefits . 2 7 , 3 0 9 , 8 2 2 . X 16a Legal fees (attach schedule) . , W b Accounting fees (attach schedule) . , > c Other professional fees (attach schedule) . [.3 57,025,171. 17 Interest . 63, 251, 245. 18 Taxes (attach schedule) (see instructions). S 19 Depreciation (attach schedule) and depletion. 15,848,187. E 0 an , , , , , , 15, 140, 678. p 1 Ings . Pr tin and publlcabons CO) Orx^erase^^ ch s ule)ATC13 ,4. 108, 107, 274 . 24 La o erat in and ad tratrve expenses. a`> (Me fS3atbroUT3.^ . , 360, 687, 749. ,' t7L t ld . O 25 on r _ 1 , 152, 955, 580. 26 Total expenses and disbursements Add lines 24 and 25 1 , 513 , 6 4 3 , 3 2 9 . 0 27 Subtract line 26 from line 12 a Excess of revenue over expenses and disbursements . 3 31 , 67 9, 90 6 . b Net investment income (if negative, enter -0-) 124,464,872. c Adjusted net income (if negative, enter -0-). SSA For Paperwork Reduction Act Notice , see instructions. Form 990 -PF (2015) 5E14101 000 RN7669 2532 7/19/2017 1:39:51 PM V 15-7.18 ^A'^ Form 990-PF (2015) THEOLLCOME TRUST 0 98-6038021 Page 2 ® Attached schedules and amounts in the Beginning of year End of year Balance Sheets description column should be for end -of-year amounts only (See instructions ) ( a) Book Value ( b) Book Value (c) Fair Market Value 7,015,140. 7,015,140. 1 Cash - non-interest-bearing . 11, 511, 7 2 0 . 2 Savings and temporary cash investments . 10,912,440. 3 Accounts receivable ► 10, 451, 430. 10, 912, 440. 10,912,440. Less allowance for doubtful accounts ► 4 Pledges receivable ► Less allowance for doubtful accounts ► 5 Grants receivable . 6 Receivables due from officers, directors , trustees , and other disqualified persons ( attach schedule) ( see instructions) . , , , 7 Other notes and loans receivable ( attach schedule) ► Less allowance for doubtful accounts ► 8 Inventories for sale or use. 490. 9 Prepaid expenses and deferred charges . 5, 907, 330. 5,066, 490. 5, 066, a 10a Investments - U S and state government obligations (attach schedule). b Investments - corporate stock ( attach schedule) . c Investments - corporate bonds ( attach schedule ). 11 Investments - land, buildings, ► and equipment basis Less accumulated depreciation ► (attach schedule) 12 Investments - mortgage loans . 13 Investments - other(attach schedule). .ATCH5 30,775,826,070. 30,760,479,530. 30,760,479,530. 14 Land , buildings , and 462,999,240. ATCH 6 eq uip ment basis ► -- -- -^ Less accumulated depreciation 151, 475, 060. 374, 585, 310. 311, 524, 180. 311, 524, 180. (attach schedule) ► ATCH 7 ) 378, 372, 060. 8,703, 970. 8,703, 970. 15 Other assets (describe ► 16 Total assets ( to be completed by all filers - see the instructions Also, see page 1, item 1) , 31,556,653,920. 31,103,701,750. 31,103,701,750. 4 4 , 7 4 8 , 19 0 . 708,918,870. 17 Accounts payable and accrued expenses . 8 18 Grants payable . 2 , 854, 755, 090. 2, 556, 239, 070. 19 Deferred revenue . 20 Loans from officers , directors , trustees, and other disqualified persons. 21 Mortgages and other notes payable ( attach schedule) . ATCH 8 ) 2,344,452,660. 2,368,259,300. J 22 Other liabilities (describe ► 23 Total liabilities ( add lines 17 through 22) . 6, 043, 955, 940. 5,633,417,240. Foundations that follow SFAS 117 , check here. ► d and complete lines 24 through 26 and lines 30 and 31. 24 Unrestricted . W 25 Temporarily restricted co 26 Permanently restricted . 0 Foundations that do not follow SFAS 117, 10. q LL t check here and complete lines 27 through 31. 0 27 Capital stock , trust principal , or current funds . 28 Paid - in or capital surplus , or land , bldg , and equipment fund . Q 29 Retained earnings , accumulated income , endowment , or other funds 30 Total net assets or fund balances (see instructions ). 25, 512, 697, 980. 25, 470, 284, 510. Z 31 Total liabilities and net assets /fund balances (see instructions ) . 31, 556, 653, 920. 31,103,701,750. FUTM Anal ysis of Changes in Net Assets or Fund Balances 1 Total net assets or fund balances at beginning of year - Part II, column (a), line 30 (must agree with end-of-year figure reported on prior year' s return ), , , , , , , , , , , , , , , , , , , , , , ,, , 1 25, 512, 697, 980. 2 Enter amount from Part I , line 27a .. .. .... .. .. .. .... ... 2 331, 679, 906. ATCH 9 3 3,583, 996,277. 3 Other increases not included in line 2 ( itemize ) ► 4 Add lines 1, 2, and 3 . 4 29,428,374,163. 5 Decreases not included in line 2 ( itemize ) loo- ATCH 10 5 3,958,089,653. 6 Total net assets or fund balances at end of year ( line 4 minus line 5 - Part II , column (b ) , line 30 . 6 25, 470, 284, 510. Form 990 -PF (2015) JSA 5E1420 1 000 RN7669 2532 7/19/2017 1: 39:51 PM V 15-7.18 THEOLLCOME TRUST is 98-6038021 Form 990-PF (2015) Page 3 Capital Gains and Losses for Tax on Investment Income (a) List and describe the kind(s) of property sold (e g real estate, (b) Hced (c) Date acquired acquired (d) Date sold 2-story brick warehouse, or common stock, 200 shs MLC Co) e yr) (mo, day, yr) D - Dournatihase (mo, day, 1a b c d e Depreciation allowed (g) Cost or other basis (h) Gain or (loss) (e) Gross sales price (f) (or allowable) plus expense of sale (e) plus (f) minus (g) a b c d e Complete only for assets showing gain in column (h) and owned by the foundation on 12/31/69 (I) Gains (Col (h) gain minus Adjusted basis (k) Excess of col (1) col (k), but not less than -0-) or (1) F M V as of 12/31/69 0) as of 12/31/69 over col 0), if any Losses (from col (h)) a b c d e If gain, also enter in Part I, line 7 2 Capital gain net income or (net capital loss) { If (loss), enter -0- in Part I, line 7 } 2 3 Net short-term capital gain or (loss) as defined in sections 1222(5) and (6) If gain, also enter in Part I, line 8, column (c) (see instructions) If (loss), enter -0- in 1 Part I, line 8 ) 3 RYA Qualification Under Section 4940 (e) for Reduced Tax on Net Investment Income (For optional use by domestic private foundations subject to the section 4940(a) tax on net investment income ) If section 4940 (d)(2) applies , leave this part blank NOT APPLICABLE DUE TO FOREIGN STATUS Was the foundation liable for the section 4942 tax on the distributable amount of any year in the base period? E]Yes No If "Yes," the foundation does not qualify under section 4940 ( e) Do not complete this part 1 Enter the aooroDrlate amount in each column for each year .
Load more

Recommended publications
  • Wellcome Trust Annual Report and Financial Statements 2017 Contents
    Annual Report and Financial Statements 2017 2 Wellcome Trust Annual Report and Financial Statements 2017 Contents Report from the Chair and the Director 5 Trustee’s Report 8 What we do 8 Review of Charitable Activities 9 Review of Investment Activities 18 Financial Review 29 Structure and Governance 34 Risk Management 37 Remuneration Report 40 Audit Committee Report 43 Independent Auditor’s Report 45 Financial Statements 58 Consolidated Statement of Financial Activities 58 Consolidated Balance Sheet 59 Statement of Financial Activities of the Trust 60 Balance Sheet of the Trust 61 Consolidated Cash Flow Statement 62 Notes to the Financial Statements 63 Reference and Administrative Details 117 3 Wellcome Trust Annual Report and Financial Statements 2017 “ At Wellcome, we believe in the power of ideas to improve health” Jeremy Farrar Director 4 Wellcome Trust Annual Report and Financial Statements 2017 Report from the Chair and the Director “Our core approach is funding people to explore great ideas, at every step of the way from discovery to impact” At Wellcome, we believe in the power of ideas to improve cause of maternal mortality in the world. It also includes health. Funded from our independent investment portfolio, supporting research in the humanities and social sciences, we support thousands of scientists and researchers in more such as a project which this year published ethical guidelines than 70 countries, as well as innovators, educators and artists. for involving pregnant women in Zika vaccine research. Together, we take on big problems, fuel imaginations and spark And resources like the Human Induced Pluripotent Stem Cell debate, working always to achieve better health for everyone.
    [Show full text]
  • The Wellcome Trust Limited Annual Report and Financial Statements Year Ended 30 September 2016
    The Wellcome Trust Limited Annual Report and Financial Statements Year ended 30 September 2016 Company number 2711000 The Wellcome Trust Limited Contents Page Governors’ Report 2 Independent Auditor’s Report 4 Profit and Loss Account 6 Balance Sheet 7 Notes to the Financial Statements 8 Administrative Details 10 1 Company number 2711000 The Wellcome Trust Limited Governors’ Report For the year ended 30 September 2016 The Governors of The Wellcome Trust Limited (the “Company”) present their report and the audited Financial Statements for the year ended 30 September 2016. This Governors’ report has been prepared in accordance with the provisions applicable to companies entitled to the small companies’ exemption. Principal Activities The activity of the Company is to act as Trustee of the Wellcome Trust, a charity registered in England and Wales (registered charity number 210183) under the Charities Act 2011. The Directors, known as Governors, are officers of the Company. The Company is limited by guarantee and has no share capital. As at 30 September 2016, there were 10 members (2015: 11), all of whom are Governors. Every member of the Company undertakes to contribute such amount as may be required (not exceeding one pound) to the assets of the Company. Results for the year The Company charges management fees to the Wellcome Trust sufficient to recover Governors' emoluments and other expenses incurred in carrying out its role as Trustee, such that the Company made neither a profit nor a loss in the current year. The Company will continue to operate in this manner in the coming year. Political and Charitable Donations The Company made no political or charitable donations during the year (2015: nil).
    [Show full text]
  • Registered Company No: 2711000
    The Wellcome Trust Limited Annual Report and Financial Statements Year ended 30 September 2015 Company number 2711000 The Wellcome Trust Limited Contents Page Governors’ Report 2 Independent Auditors’ Report 4 Profit and Loss Account 6 Balance Sheet 7 Notes to the Financial Statements 8 Administrative Details 10 1 Company number 2711000 The Wellcome Trust Limited Governors’ Report For the year ended 30 September 2015 The Governors of The Wellcome Trust Limited (the “Company”) present their report and the audited Financial Statements for the year ended 30 September 2015. Principal Activities The activity of the Company is to act as Trustee of the Wellcome Trust, a charity registered in England and Wales (registered charity number 210183) under the UK Charities Act 2011. The Directors, known as Governors, are the only employees of the Company. The Company is limited by guarantee and has no share capital. As at 30 September 2015, there were 11 members (2014: 11), all of whom are Governors. Every member of the Company undertakes to contribute such amount as may be required (not exceeding one pound) to the assets of the Company. Results for the year The Company charges management fees to the Wellcome Trust sufficient to recover Governors' emoluments and other expenses incurred in carrying out its role as Trustee, such that the Company made neither a profit or a loss in the current year. The Company will continue to operate in this manner in the coming year. Political and Charitable Donations The Company made no political or charitable donations during the year (2014: nil). Internal Control and Risk Management The Company is not exposed to any major risks.
    [Show full text]
  • Michael Paul Stryker
    BK-SFN-NEUROSCIENCE_V11-200147-Stryker.indd 372 6/19/20 2:19 PM Michael Paul Stryker BORN: Savannah, Georgia June 16, 1947 EDUCATION: Deep Springs College, Deep Springs, CA (1964–1966) University of Michigan, Ann Arbor, MI, BA (1968) Massachusetts Institute of Technology, Cambridge, MA, PhD (1975) Harvard Medical School, Boston, MA, Postdoctoral (1975–1978) APPOINTMENTS: Assistant Professor of Physiology, University of California, San Francisco (1978–1983) Associate Professor of Physiology, UCSF (1983–1987) Professor of Physiology, UCSF (1987–present) Visiting Professor of Human Anatomy, University of Oxford, England (1987–1988) Co-Director, Neuroscience Graduate Program, UCSF (1988–1994) Chairman, Department of Physiology, UCSF (1994–2005) Director, Markey Program in Biological Sciences, UCSF (1994–1996) William Francis Ganong Endowed Chair of Physiology, UCSF (1995–present) HONORS AND AWARDS (SELECTED): W. Alden Spencer Award, Columbia University (1990) Cattedra Galileiana (Galileo Galilei Chair) Scuola Normale Superiore, Italy (1993) Fellow of the American Association for the Advancement of Science (1999) Fellow of the American Academy of Arts and Sciences (2002) Member of the U.S. National Academy of Sciences (2009) Pepose Vision Sciences Award, Brandeis University (2012) RPB Stein Innovator Award, Research to Prevent Blindness (2016) Krieg Cortical Kudos Discoverer Award from the Cajal Club (2018) Disney Award for Amblyopia Research, Research to Prevent Blindness (2020) Michael Stryker’s laboratory demonstrated the role of spontaneous neural activity as distinguished from visual experience in the prenatal and postnatal development of the central visual system. He and his students created influential and biologically realistic theoretical mathematical models of cortical development. He pioneered the use of the ferret for studies of the central visual system and used this species to delineate the role of neural activity in the development of orientation selectivity and cortical columns.
    [Show full text]
  • 2012 IMP Research Report
    RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY VIENNA BIOCENTER 2012 CONTENTS Introduction ..............................................................................2 The reluctant heretic..............................................................4 Working together, even at a distance ..............................6 ReseArcH GroUPS Meinrad Busslinger .................................................................8 Tim Clausen ............................................................................ 10 Carrie Cowan ...........................................................................12 Barry Dickson ......................................................................... 14 Christine Hartmann ............................................................. 16 Wulf Haubensak .................................................................... 18 Katrin Heinze .......................................................................... 20 David Keays .............................................................................22 Krystyna Keleman ................................................................. 24 Thomas Marlovits ................................................................. 26 Jan-Michael Peters ............................................................... 28 Simon Rumpel .......................................................................30 Alexander Stark ..................................................................... 32 Andrew Straw .........................................................................34
    [Show full text]
  • The P75 Neurotrophin Receptor Negatively Modulates Dendrite Complexity and Spine Density in Hippocampal Neurons
    The Journal of Neuroscience, October 26, 2005 • 25(43):9989–9999 • 9989 Development/Plasticity/Repair The p75 Neurotrophin Receptor Negatively Modulates Dendrite Complexity and Spine Density in Hippocampal Neurons Marta Zagrebelsky,1 Andreas Holz,2 Georg Dechant,3 Yves-Alain Barde,4 Tobias Bonhoeffer,1 and Martin Korte1 Departments of 1Cellular and Systems Neurobiology and 2Neuroimmunology, Max Planck Institute of Neurobiology, D-82152 Martinsried, Germany, 3Institute for Neuroscience, Innsbruck Medical University, A-6020 Innsbruck, Austria, and 4Division of Pharmacology/Neurobiology, Biozentrum, University of Basel, CH-4003 Basel, Switzerland The correlation between functional and structural neuronal plasticity is by now well documented. However, the molecular mechanisms translating patterns of neuronal activity into specific changes in the structure of neurons remain unclear. Neurotrophins can be released in an activity-dependent manner, and they are capable of controlling both neuronal morphology and functional synaptic changes. They are thus attractive molecules to be studied in the context of synaptic plasticity. In the CNS, most of the work so far has focused on the role of BDNF and of its tyrosine kinase B receptor (TrkB), but relatively little is known about the function of the pan-neurotrophin receptor p75 NTR. In this study, we show in loss-of-function experiments that postnatal hippocampal pyramidal cells in two mutant lines of p75 NTR have a higher spine density and greater dendritic complexity than wild-type (WT) mice. Conversely, in a gain-of-function approach, p75 NTR overexpression in WT neurons significantly reduces dendritic complexity, as well as spine density in all dendritic compartments. These results show that p75 NTR negatively modulates dendritic morphology in adult hippocampal pyramidal neurons and documents a new case of functional antagonism between Trk and p75 NTR signaling.
    [Show full text]
  • Annual Report and Financial Statements
    Financial year 2014 Annual Report and Financial Statements Contents Chairman’s Statement 02 Trustee’s Report 04 Vision and objects, mission, focus areas and 04 challenges Financial Review 05 Review of Past and Future Activities 09 Review of Investment Activities 15 Structure and Governance 26 Remuneration Report 32 Social Responsibility 34 Independent Auditors 36 Audit Committee Report 37 Independent Auditors’ Report 39 Consolidated Statement of Financial Activities 45 Consolidated Balance Sheet 46 Statement of Financial Activities of the Trust 47 Balance Sheet of the Trust 48 Consolidated Cash Flow Statement 49 Notes to the Financial Statements 50 Reference and Administrative Details 90 Chairman’s Statement The best research for better health Creating cultures for research who we are and what we do, and has at the frontiers of medicine helped us achieve an ever more and health integrated approach within. This was a challenging first year for The built environment is a huge our Director, Dr Jeremy Farrar. As a influence on the way we work. The clinician and a researcher with Francis Crick Institute, a partnership expertise across global health and between the Trust, the Medical infectious diseases, his skills were in Research Council, Cancer Research high demand, particularly when it UK and several of London’s became clear that the Ebola virus universities, opens next year. It, too, outbreak in West Africa this year was has been designed to encourage an epidemic of unprecedented interdisciplinary working. As well as proportion. At the same time, Jeremy enhancing research partnerships, the was listening carefully to the views of Crick will bring biomedical research We have streamlined the his new colleagues at the Wellcome together with clinical skills and many framework for our funding Trust and of the research community other scientific disciplines.
    [Show full text]
  • Spaced Training Enhances Memory and Prefrontal Ensemble Stability in Mice
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.17.417451; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 2 Spaced training enhances memory and prefrontal ensemble stability in mice 1,2 1 1 1 3 Annet Glas , Mark H¨ubener , Tobias Bonhoeffer , Pieter M. Goltstein 4 Author Affiliations 1 5 Max Planck Institute of Neurobiology, Martinsried, Germany 2 6 Graduate School of Systemic Neurosciences, Martinsried, Germany 7 Lead Contacts 8 Tobias Bonhoeffer, [email protected] 9 Pieter Goltstein, [email protected] 10 Summary 11 Memory is substantially improved when learning is distributed over time, an effect called \spacing effect". So 12 far it has not been studied how spaced learning affects neuronal ensembles presumably underlying memory. 13 In the present study, we investigate whether trial spacing increases the stability or size of neuronal ensembles. 14 Mice were trained in the \everyday memory" task, an appetitive, naturalistic, delayed matching-to-place task. 15 Spacing trials by 60 minutes produced more robust memories than training with shorter or longer intervals. 16 c-Fos labeling and chemogenetic inactivation established the necessity of the dorsomedial prefrontal cortex 17 (dmPFC) for successful memory storage. In vivo calcium imaging of excitatory dmPFC neurons revealed that 18 longer trial spacing increased the similarity of the population activity pattern on subsequent encoding trials 19 and upon retrieval.
    [Show full text]
  • Download Final Program with Abstracts (Pdf, 5.5
    NEUROSCIENCE WINTER CONFERENCE 16th International Sölden Austria !April 8 -April 12 2014 Hotel Das Central !Final Scientific Program ! ! !Time schedule of keynote lectures and symposia !List of poster presentations !List of participants !Abstracts speakers !Abstracts posters !Program Commi*ee: !Contributors: !Exhibitors: - Abcam plc Tobias Bonhoeffer - Austrian Neuroscience AssociaBon ! Nils Brose - Das Central ! Alois Saria - Lundbeck Austria GmbH ! Stephan Schwarzacher ! ! ! ! - InternaBonal Society for ! Neurochemistry Organizer: brainplatform.net e.U. ! ! ! ! ! - Andor Technology Ltd. Conference Chair: - Tocris Bioscience !Alois Saria, Austria !- Novus Biologicals "1 ! ! ! ! Tuesday Wednesday Thursday April 8 April 9 Afternoon April 10 Morning ! ! ! !15:00 - 16:30 RegistraBon 13:20 - 15:20 Symposium 4 08:15 - 09:00 Keynote Lecture 2 16:30 - 17:00 Welcome Cocktail ! ! Glutamatergic transmission in schizophrenia Zach Mainen (Portugal) Neural circuits for 17:00 - 19:00 Symposium 1 Chair: Robert Schwarcz (USA) spontaneous acCon Cming in the frontal cortex ! ! Rapid cross-talk between synapBc receptors: A ChrisBne Konradi (USA) Hippocampal 09:00 - 11:00 Symposium 6 key path of synapBc plasBcity interneurons and mitochondrial abnormaliCes in ! 2+ Chair: Dmitri Rusakov (UK) psychoCc disorders Nanophysiology of presynapBc Ca signaling ! Joseph Coyle (USA) Serine racemase knockout Chair: Tobias Moser (Germany) Dmitri Rusakov (UK) A sub-millisecond mGluR- mice: A mouse model of NMDA receptor ! ++ NMDAR dialog triggering LTP hypofuncCon Erwin Neher (Germany) Ca -handling and Julie Perroy (France) Cross-talk between Robert Schwarcz (USA) The role of endogenous superpriming at the Calyx of Held glutamate receptors kynurenic acid in hippocampal funcCon and Jakob Neef (Germany) Number, topography and 2+ Antoine Triller (France) Control of synapCc dysfuncon coupling to release of Ca channels at hair cell strength by gypherin W.
    [Show full text]
  • ARC Centre of Excellence for Integrative Brain Function
    ARC Centre of Excellence for Integrative Brain Function ARC Centre ANNUAL REPORT ANNUAL REPORT 2017 ANNUAL REPORT ARC CENTRE OF EXCELLENCE 2017FOR INTEGRATIVE BRAIN FUNCTION Cover image: Art Competition Category 2, 3rd place by Gabby, age 7 COLLABORATING, PARTNER AND AFFILIATE ORGANISATIONS Collaborating organisations Partner organisations Affiliate organisations The ARC Centre of Excellence for Integrative Brain Function Annual Report 2017 Contents INTRODUCTION About 4 Vision and Mission 6 Governance 7 Message from the Director 8 Message from the Chair 10 PERSONNEL 12 Centre Staff 16 Collaboration Network 18 RESEARCH REPORT 20 Research Themes 22 Research Projects 24 Publications 30 Presentations 34 CENTRE PROGRAMS 42 Education 44 The Brain Dialogue 48 Neuroethics 52 Neuroinformatics 54 Industry Engagement 56 Gender, Equity and Diversity 57 Centre Events 58 Sponsorship 60 LOOKING AHEAD 2018 62 KEY PERFORMANCE INDICATORS 64 FINANCE AND FUNDING 66 INTRODUCTION About the Centre Understanding how the brain interacts with the world is one of the greatest challenges of the 21st century. To address this challenge, brain researchers from around the country, with expertise across multiple disciplines have joined forces to establish the ARC Centre of Excellence for Integrative Brain Function (Brain Function CoE). The Centre has developed an integrated research program aimed at studying the brain across a multitude of spatial and temporal scales. By integrating research across scales and disciplines, the outcomes of the Centre will provide a more comprehensive understanding of how the brain functions as a whole. The Centre's research has focused on understanding how the brain integrates information at multiple scales, from nerve cell electrical and biochemical activity through patterns of activity in large scale circuit networks to yield complex behaviour in the three key daily-life functions of attention, prediction, and decision behaviour.
    [Show full text]
  • Active Dendrites Enable Strong but Sparse Inputs to Determine Orientation Selectivity
    Active dendrites enable strong but sparse inputs to determine orientation selectivity Lea Goetza, Arnd Rotha, and Michael Häussera,1 aWolfson Institute for Biomedical Research, University College London, London WC1E 6BT, United Kingdom Edited by Tobias Bonhoeffer, Max Planck Institute of Neurobiology, Munich, Germany, and approved June 9, 2021 (received for review August 16, 2020) The dendrites of neocortical pyramidal neurons are excitable. How- trigger dendritic Na+ spikes and NMDA spikes. We also provide ever, it is unknown how synaptic inputs engage nonlinear dendritic a quantitative explanation for how these dendritic spikes determine mechanisms during sensory processing in vivo, and how they in turn neuronal output in vivo. Our results show that dendritic spikes can influence action potential output. Here, we provide a quantitative be triggered by a surprisingly small number of synaptic inputs—in account of the relationship between synaptic inputs, nonlinear den- some cases even by single synapses. We also find that during sensory dritic events, and action potential output. We developed a detailed processing, already few dendritic spikes are effective at driving pyramidal neuron model constrained by in vivo dendritic recordings. somatic output. Overall, this strategy allows a remarkably small We drive this model with realistic input patterns constrained by sensory number of strong synaptic inputs to dominate neural output, responses measured in vivo and connectivity measured in vitro. We which may reduce the number of neurons required to represent a show mechanistically that under realistic conditions, dendritic Na+ and given sensory feature. NMDA spikes are the major determinants of neuronal output in vivo. We demonstrate that these dendritic spikes can be triggered by a Results surprisingly small number of strong synaptic inputs, in some cases An Active Dendritic Model Reproduces Responses to Visual Stimulation.
    [Show full text]
  • Dear Prime Minister Johnson, for the Last Four Years, the European and UK Research Community Has Been Calling for Continued Scientific Cooperation Post-Brexit
    15 October 2020 Rt Hon Boris Johnson MP Prime Minister 10 Downing Street London SW1A 2AA Dear Prime Minister Johnson, For the last four years, the European and UK research community has been calling for continued scientific cooperation post-Brexit. In this late state of the negotiations, we urge you to find a compromise. This is the final opportunity to use these negotiations to ensure that future generations everywhere can continue to benefit from the results of UK-EU scientific collaboration. Our shared experiences tell us that we should now be building on the successful EU-UK collaborations we have known for decades, not scaling back. We must continue to work together to tackle shared global challenges, including the current pandemic, where research is the only exit strategy. We’ve found it encouraging that both of your teams have continued to discuss research in the negotiations and have committed to the principle of full UK participation in Horizon Europe. This mutual mandate must now translate into action. A practical agreement can, and must, be found. This summer, over 100 organisations and researchers signed a compromise statement that proposed solutions to some of the sticking points in negotiations. These included ensuring fair financial contributions, accepting EU oversight of programme funds, and agreeing to introduce reciprocal mobility arrangements. In the current political context, it will be most important to build trust on both sides, including the UK demonstrating its commitment to the programme. A decision against UK participation in Horizon Europe would have fundamental and long- term consequences. It would fracture European research collaboration, undermine the ambition of the programme and threaten its future success.
    [Show full text]